Please join Nektar Therapeutics for a virtual investor and analyst event to discuss the Type 1 Diabetes Mellitus (T1D) treatment landscape and their announcement this morning [Link to the Announcement].

Nektar’s Chief Research & Development Officer, Jonathan Zalevsky, Ph.D., will be hosting the webcasted event. He will be joined by leading endocrinology experts, including:

• Dr. Kevan Herold, TrialNet Chair and C.N.H. Long Professor of Immunobiology and Medicine at Yale University at Yale School of Medicine;
• Dr. Megan Levings, Professor, Department of Surgery and School of Biomedical Engineering at The University Of British Columbia; and,
• Dr. Daniel Moore, Associate Professor of Pediatrics and Pathology, Microbiology and Immunology at Vanderbilt University Medical Center.

A live question and answer session will follow the formal presentations.